Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2, open-label, multicenter, non-randomized pilot study is to evaluate
the efficacy (in terms of MRD negative CR rate after Intensification therapy) and safety of
Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo
high-risk multiple myeloma (DNHRMM) patients.